A multi-cohort validated OXPHOS signature predicts survival and immune profiles in grade II/III glioma patients.

ABSTRACT:

Introduction

Grade II/III gliomas are invasive brain tumors with a high risk of malignant progression and significant clinical heterogeneity, highlighting the urgent need for reliable prognostic biomarkers to guide personalized treatment strategies. This study aimed to investigate the molecular mechanisms driving glioma progression and to identify potential therapeutic targets.

Methods

We analyzed 200 mitochondrial oxidative phosphorylation (OXPHOS)-related genes in 512 grade II/III glioma samples from The Cancer Genome Atlas (TCGA). Consensus clustering identified two distinct molecular subtypes (C1 and C2). Differentially expressed genes (DEGs) between subtypes were determined using the limma package. The immune cell composition and tumor microenvironment (TME) characteris

SUBMITTER: Mou J 

PROVIDER: S-EPMC12354405 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature